Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, dose-ranging Phase 2b trial in patients with IPF and in a parallel cohort of patients with progressive fibrosing-interstitial lung disease

Next Previous
Trial Profile

A randomized, double-blind, dose-ranging Phase 2b trial in patients with IPF and in a parallel cohort of patients with progressive fibrosing-interstitial lung disease

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 03 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Taladegib (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Therapeutic Use
  • Sponsors Endeavor BioMedicines; Endeavor Pharmaceuticals

Most Recent Events

  • 24 Apr 2024 According to an Endeavor BioMedicines media release, the company plans to initiate a Phase 2b trial in patients with IPF and in parallel a cohort of patients with PPF in 2024.
  • 13 Jan 2021 New trial record
  • 07 Jan 2021 According to an Endeavor BioMedicines media release, this study will be starting in 2022. The company has received financing to conduct this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top